Aim: To evaluate the efficacy and tolerability of rac-hopantenic acid (pantogam activ) in patients with mixed anxiety-depressive disorder and anxiety-depressive disorder with chronic cerebral ischemia.
Material And Methods: A total of 50 patients were examined (30 patients in the main group, 20 patients in the control one). All patients received standard therapy with SSRI antidepressants. Rac-hopantenic acid at a daily dose of 1200 mg was included in the complex therapy of patients of the main group. Duration of the therapy with rac-hopantenic acid was 21 days. Psychopathological, psychometric and detailed somatic examinations were performed.
Results: In the main group, the combination of pantogam activ and antidepressants promoted distinct balanced nootropic, antidepressant and anxiolytic effects, as well as the improvement of health outcomes. The reduced total number of adverse events (less frequent drowsiness and headaches) was noted as well.
Conclusion: The rapid and reliable reduction of anxiety, depression and cognitive impairment during concomitant therapy with antidepressants and pantogam activ was identified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro201611611145-57 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Possible applications of rac-hopantenic acid in the treatment of cognitive, anxiety and depressive disorders in patients with essential arterial hypertension].
Zh Nevrol Psikhiatr Im S S Korsakova
March 2019
Sechenov First Moscow State Medical University, Moscow, Russia, Pirogov Russian National Research Medical University, Clinical and Research Center of Gerontology, Moscow, Russia.
Essential arterial hypertension (AH) is one of the main risk factors for the development of cognitive impairment and dementia. Cognitive decline is an early sign of brain damage as a target organ of hypertension, it occurs even in patients with uncomplicated hypertension with minimal duration of disease. Cognitive impairment progresses with increasing age and hypertension duration, as well as in non-controlled AH.
View Article and Find Full Text PDF[Possible applications of rac-hopantenic acid in the treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2018
Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
Aim: To evaluate the efficacy and tolerability of rac-hopantenic acid (pantogam activ) in patients with mixed anxiety-depressive disorder and anxiety-depressive disorder with chronic cerebral ischemia.
Material And Methods: A total of 50 patients were examined (30 patients in the main group, 20 patients in the control one). All patients received standard therapy with SSRI antidepressants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!